A brazilian experience in response to optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis

Journal of Acquired Immune Deficiency Syndromes

Volumn 50, Issue 3, 2009, Pages 340-

  Schmaltz, Carolina Arana Stanis ^a,b   Lopes, Guilherme Santoro ^b   Rolla, Valéria Cavalcanti ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN;

ANTIVIRAL THERAPY; BRAZIL; DISEASE ASSOCIATION; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LETTER; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; TREATMENT DURATION; TUBERCULOSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; DRUG ADMINISTRATION; NOTE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRAZIL; DRUG ADMINISTRATION SCHEDULE; HUMANS; TUBERCULOSIS;

EID: 63149132681     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819001d5     Document Type: Letter

References (8)

1. Lawn SD, Wood R. Optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis. There may be more than one right answer. J Acquir Immune Defic Syndr. 2007;46:121-123.
2. Schiffer JT, Sterling TR. Response to "optimum time to initiate antiretroviral therapy in patients with HIV-associated tuberculosis. There may be more than one right answer." J Acquir Immune Defic Syndr. 2007;46:122-123.
3. Lawn SD, Myer L, Bekker LG. et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-1612.
4. Lawn SD, Myer L, Orrell C. et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19:2141-2148.
5. Schiffer JT, Sterling TR. Timing on antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr. 2007;44:229-234.
6. Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327-341.
7. Pedral-Sampaio DB, Netto EM, Brites C, et al. Treating tuberculosis in AIDS patients: when to start and how long to keep giving drugs? AIDS. 2002; 16:1845.
8. Lawn SD, Myer L, Bekker LG. et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21:335-341.